PharmaEssentia Data Show 55% of First-Line BESREMi Patients With Polycythemia Vera Remain on Treatment at Two Years

• PharmaEssentia will present six research posters October 29 at the International Congress on Myeloproliferative Neoplasms, running October 29-30 in Brooklyn, New York.
• Real-world data showed more than half of polycythemia vera patients remained on first-line BESREMi at two years, with greater persistence among younger patients.
• Japanese trial analyses linked faster BESREMi dose escalation to greater reductions in a disease-driving mutation, with similar blood count control.
• A Chinese real-world study found improving blood count responses with BESREMi over time; reported adverse events were mild or moderate.
• Separate analyses highlighted limited treatment options in essential thrombocythemia and persistent thrombosis risk with hydroxyurea, underscoring unmet needs across both diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610191003BIZWIRE_USPR_____20261019_BW222358) on October 19, 2026, and is solely responsible for the information contained therein.